Enrolling by invitationNo phase
CHU Dual-Energy Ablation in Ventricular Arrhythmia
Key facts
- Who runs it
- Shanghai MicroPort EP MedTech Co., Ltd.
- Where
- Ningbo, ChinaSee the site
- Trial code
- Status
- Enrolling by invitation
- People taking part
- 10 people, planned
- Started
- 3 Feb 2026
- Planned end
- 31 Oct 2026
- Type of study
- Interventional
- Treatments tested
- ablation
- Record updated
- 31 March 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Patient age ≥ 18 years and ≤ 75 years；
- Clinically diagnosed with tachyarrhythmia, specifically idiopathic ventricular arrhythmia；
- Recurrent disease with obvious symptoms prior to enrollment
- Failure to respond to or intolerance of at least one antiarrhythmic drug
- Fully understand the treatment plan, voluntarily sign the informed consent form, and agree to undergo the examinations, procedures and follow-up as required by the protocol
Who cannot take part
- Previous atrial septal repair or atrial myxoma
- Patients who have participated in or are currently participating in other clinical trials within 3 months prior to enrollment
- History of ventricular flutter or ventricular fibrillation
- Presence of structural heart disease or organic heart disease, including hypertrophic cardiomyopathy, dilated cardiomyopathy, ischemic cardiomyopathy, rheumatic heart disease, and congenital heart disease
- Carrying an active implantable device in the body (e.g., cardiac pacemaker, ICD, etc.)
- Patients with documented cerebrovascular disease within the past 6 months (including cerebral hemorrhage, stroke, transient ischemic attack)
- Patients with cardiovascular events within the past 3 months (including acute myocardial infarction, percutaneous coronary intervention or coronary artery bypass grafting, prosthetic valve replacement or repair, atrial or ventricular incision)
- Patients with acute or severe systemic infection
- Patients with severe hepatic or renal disease, malignant tumor, or end-stage disease, who, in the investigator's judgment, may interfere with the treatment, evaluation, or compliance of this trial
- Patients with significant bleeding tendency, hypercoagulable state, or severe hematological disorders
- Patients with other conditions deemed inappropriate for participation in this trial by the investigator
- Left ventricular ejection fraction (LVEF) ≤ 40%
- Diagnosis of long QT syndrome or arrhythmogenic cardiomyopathy
- NYHA functional class Ⅲ-Ⅳ
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in China
- The First Affiliated Hospital of Ningbo UniversityNingbo, ChinaNo longer taking part
About the trial
What the trial wants to find out
The objective of this study is to evaluate the safety of the dual-energy ablation catheter manufactured by Shanghai MicroPort EP Medical Technology Co., Ltd. in the treatment of tachyarrhythmias.
The group in the trial
- Catheter ablationTreatment being tested
All enrolled subjects will undergo radiofrequency or pulsed ablation for idiopathic ventricular arrhythmias using the investigational catheter.
Treatment: ablation
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Contact-Force Guided Hybrid-Dual-Energy Ultra-Saline-Irrigated Ablation First-in-Man for Ventricular Arrhythmia: CHU VA
- Fit questions
- Built from NCT07503769, who can take part
- Record updated
- 31 March 2026